-
Product Insights
CPG – Cham Papieri-Areals Mixed-Use Development – Zug
Equip yourself with the essential tools needed to make informed and profitable decisions with our CPG - Cham Papieri-Areals Mixed-Use Development - Zug report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
CPG – 30 Broad Street Underground Family Activity Center – New York
Equip yourself with the essential tools needed to make informed and profitable decisions with our CPG - 30 Broad Street Underground Family Activity Center - New York report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DUET-201 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DUET-201 in Mantle Cell Lymphoma Drug Details: CpG-STAT3 siRNA is under investigation for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DUET-201 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DUET-201 in Follicular Lymphoma Drug Details: CpG-STAT3 siRNA is under investigation for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DUET-201 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DUET-201 in Diffuse Large B-Cell Lymphoma Drug Details: CpG-STAT3 siRNA is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DUET-201 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DUET-201 in Marginal Zone B-cell Lymphoma Drug Details: CpG-STAT3 siRNA is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DUET-201 in B-Cell Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DUET-201 in B-Cell Non-Hodgkin Lymphoma Drug Details: CpG-STAT3 siRNA is under investigation for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Z-1018 in Herpes Zoster (Shingles)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Z-1018 in Herpes Zoster (Shingles) Drug Details:Z-1018 is under development for the prevention of herpes zoster...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-7909 in Anthrax
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-7909 in Anthrax Drug Details: AV-7909 (NuThrax) is under development for the prevention of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Tetanus
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Tetanus Drug Details: Vaccine candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Diphtheria
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Diphtheria Drug Details: Vaccine candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Pertussis (Whooping Cough)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Diphtheria + Pertussis (Acellular) + Tetanus) Vaccine in Pertussis (Whooping Cough) Drug Details: Vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NGN-401 in Rett Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NGN-401 in Rett Syndrome Drug Details: NGN-401 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAC-001 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAC-001 in Solid Tumor Drug Details: TAC-001 is under development for the treatment of advanced...
-
Company Profile
![]()
JDE Peet’s NV – Company Profile
JDE Peet's NV (JDE Peets's), formerly JDE Peet's BV, is a provider of coffee and tea products and solutions. The company offers products such as coffee, tea, and ready-to-drink beverages. It provides its products under brands such as Jacobs, Douwe Egberts, Peet's Coffee, Senseo, Omnia, Tassimo, and Pickwick etc. The Company markets its products and solutions through a go-to-market approach across the consumer-packaged-goods (CPG), out-of-home, retail stores, and online sales channels. With a distinctive brand building model to develop communication...
Add to Basket -
Company Profile
![]()
Checkmate Pharmaceuticals Inc – Company Profile
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals), a subsidiary of Regeneron Pharmaceuticals Inc, is a biotechnology company that discover and develop novel approaches for cancer immunotherapy. The company’s lead product, CMP-001, is a CpG oligonucleotide (CpG-A) that activates differentiated potent activator TLR9 present in tumor infiltrating plasmacytoid dendritic cells (pDC). Checkmate Pharmaceuticals is investigating CMP-001 in combination with various drugs such as nivolumab and pembrolizumab for treatment of PD-1 refractory melanoma, first-line melanoma and Head and Neck Squamous Cell Carcinoma. The company’s...
Add to Basket -
Sector Analysis
Myanmar Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2027
Myanmar Construction Market Report Overview The Myanmar construction market size was $7.9 billion in 2022. The market is projected to achieve an AAGR of more than 6% during 2024-2027, supported by investment in electricity and transport infrastructure projects. Myanmar Construction Market Outlook, 2022-2027 For more insights into the Myanmar construction market forecast, download a free report sample The Myanmar construction market research report provides detailed market analysis, information, and insights into the Myanmar construction industry, including the growth prospects of...
-
Company Profile
![]()
UiPath Inc – Company Profile
UiPath Inc (UiPath) is a provider of enterprise robotic process automation (RPA) software solutions. The company’s products include UiPath Studio, which enables users to design automation processes visually, UiPath Robots, which execute the processes built in Studio, similar to humans and UiPath Orchestrator, a web application that allows users to deploy, monitor, plan and manage robots and processes. It also provides automation solutions for processes such as accounts payables, claims processing, finance and accounting, healthcare payer and contact center automation....
Add to Basket -
Company Profile
![]()
Amazon Web Services Inc – Company Profile
Amazon Web Services Inc (AWS), a subsidiary of Amazon.com, Inc, provides cloud computing services. The company offers a comprehensive range of cloud infrastructure services including computing, storage, databases, networking, analytics, mobile, developer tools, augmented reality and virtual reality, robotics, game tech, machine learning, management tools, content delivery, media services, customer engagement, app streaming and security, identity and compliance. AWS serves to products and services to automotive, digital marketing, telecommunications, education, government, retail, financial services, media and entertainment, gaming, CPG, health...
Add to Basket -
Company Profile
![]()
Quotient Technology Inc – Company Profile
Quotient Technology Inc (Quotient) is an operator of digital marketing platform. The company offers media solutions and digital coupons, which include digital printable coupons, coupon codes, digital paperless coupons and loyalty card promotions. Its digital media services includes shopper media offerings, national media offerings, DOOH offerings and sponsored search offerings. Quotient offers its products and services to consumer packaged goods (CPG) brands, shoppers and retailers. It provides a digital platform to engage with their shoppers across their mobiles, e-commerce, websites,...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.